341 related articles for article (PubMed ID: 30926959)
1. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
Cicali EJ; Weitzel KW; Elsey AR; Orlando FA; Vinson M; Mosley S; Smith DM; Davis R; Drum L; Estores D; Franciosi JP; Hagen MG; Jerkins GJ; Mercado ES; Nainaparampil J; Padron A; Rosenberg EI; Wright A; Schmidt SO; Mathews CA; Cavallari LH; Johnson JA
Genet Med; 2019 Oct; 21(10):2264-2274. PubMed ID: 30926959
[TBL] [Abstract][Full Text] [Related]
2. Institutional profile: University of Florida Health Personalized Medicine Program.
Cavallari LH; Weitzel KW; Elsey AR; Liu X; Mosley SA; Smith DM; Staley BJ; Winterstein AG; Mathews CA; Franchi F; Rollini F; Angiolillo DJ; Starostik P; Clare-Salzler MJ; Nelson DR; Johnson JA
Pharmacogenomics; 2017 Apr; 18(5):421-426. PubMed ID: 28346068
[TBL] [Abstract][Full Text] [Related]
3. Challenges in Ordering and Interpreting Pharmacogenomic Tests in Clinical Practice.
Moyer AM; Rohrer Vitek CR; Giri J; Caraballo PJ
Am J Med; 2017 Dec; 130(12):1342-1344. PubMed ID: 28757317
[No Abstract] [Full Text] [Related]
4. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Cavallari LH; Van Driest SL; Prows CA; Bishop JR; Limdi NA; Pratt VM; Ramsey LB; Smith DM; Tuteja S; Duong BQ; Hicks JK; Lee JC; Obeng AO; Beitelshees AL; Bell GC; Blake K; Crona DJ; Dressler L; Gregg RA; Hines LJ; Scott SA; Shelton RC; Weitzel KW; Johnson JA; Peterson JF; Empey PE; Skaar TC;
Genet Med; 2019 Oct; 21(10):2255-2263. PubMed ID: 30894703
[TBL] [Abstract][Full Text] [Related]
5. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
6. Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.
Cicali EJ; Elchynski A; Thomas CD; Alam B; Dalton R; Davis R; Eken E; Estores D; Nguyen K; Cavallari LH; Wiisanen K
Am J Health Syst Pharm; 2023 Jul; 80(15):994-1003. PubMed ID: 37166240
[TBL] [Abstract][Full Text] [Related]
7. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Empey PE; Stevenson JM; Tuteja S; Weitzel KW; Angiolillo DJ; Beitelshees AL; Coons JC; Duarte JD; Franchi F; Jeng LJB; Johnson JA; Kreutz RP; Limdi NA; Maloney KA; Owusu Obeng A; Peterson JF; Petry N; Pratt VM; Rollini F; Scott SA; Skaar TC; Vesely MR; Stouffer GA; Wilke RA; Cavallari LH; Lee CR;
Clin Pharmacol Ther; 2018 Oct; 104(4):664-674. PubMed ID: 29280137
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
9. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
Bousman CA; Jaksa P; Pantelis C
Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
[TBL] [Abstract][Full Text] [Related]
10. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
11. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
12. Implementing a personalized medicine program in a community health system.
Dressler LG; Bell GC; Ruch KD; Retamal JD; Krug PB; Paulus RA
Pharmacogenomics; 2018 Nov; 19(17):1345-1356. PubMed ID: 30345883
[TBL] [Abstract][Full Text] [Related]
13. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic.
Goodson R; Wagner J; Sandritter T; Staggs VS; Soden S; Nadler C
J Dev Behav Pediatr; 2023 Oct-Nov 01; 44(8):e505-e510. PubMed ID: 37807195
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
16. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT
Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969
[TBL] [Abstract][Full Text] [Related]
17. Implementation of wide-scale pharmacogenetic testing in primary care.
Natasha Petry ; Baye J; Aifaoui A; Wilke RA; Lupu RA; Savageau J; Gapp B; Massmann A; Hahn D; Hajek C; Schultz A
Pharmacogenomics; 2019 Aug; 20(12):903-913. PubMed ID: 31453774
[TBL] [Abstract][Full Text] [Related]
18. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
19. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
20. A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
Weitzel KW; Duong BQ; Arwood MJ; Owusu-Obeng A; Abul-Husn NS; Bernhardt BA; Decker B; Denny JC; Dietrich E; Gums J; Madden EB; Pollin TI; Wu RR; Haga SB; Horowitz CR
Pharmacogenomics; 2019 Oct; 20(15):1103-1112. PubMed ID: 31588877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
